<p>A cohort of early RA patients (n = 73) were recruited for investigation. Baseline characteristics of the cohort is summarised in column [Entire cohort]. Patients with EULAR response data at week 14 post-initiation of therapy (n = 42) were furthermore split into non-responders [NR] or moderate/good responders [MOD/GOOD] and baseline characteristics in each subgroup analysed separately. Statistically significant differences between the two EULAR response subgroups [NR vs. MOD/GOOD] were examined. (‡) fishers statistical test (φ) mann-whitney U test.</p
Objectives: Trial data have provided an evidence base to guide early treatment in RA. Few studies ha...
ObjectivesTrial data have provided an evidence base to guide early treatment in RA. Few studies have...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Objective To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA...
<p>Anti-CCP, anti-cyclic citrullinated peptide antibody; RF, rheumatoid factor; CRP, C-reactive prot...
<p>Patients were grouped according to the number of fulfilled parameters (corticosteroids therapy, n...
<p>Values are mean ± sd unless otherwise indicated. *values are reported as mean ± sd (median).</p><...
*<p>Except where indicated otherwise, values are expressed as the mean (range).</p
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Baseline characteristics of patients with early RA across DAS28-ESR trajectory groups.</p
Background. In rheumatoid arthritis (RA), prompt diagnosis and initiation of disease-modifying treat...
<p>Values are mean values (SD) or number of patients (%).</p>1<p>Eular Guideline: 1st rheumatologist...
Objective. To compare baseline characteristics, responses and drug survival in patients with early R...
AIMS To develop a population model describing the disease activity (DAS28) time course in patients w...
Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of m...
Objectives: Trial data have provided an evidence base to guide early treatment in RA. Few studies ha...
ObjectivesTrial data have provided an evidence base to guide early treatment in RA. Few studies have...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...
Objective To identify predictors of response to methotrexate (MTX) in early rheumatoid arthritis (RA...
<p>Anti-CCP, anti-cyclic citrullinated peptide antibody; RF, rheumatoid factor; CRP, C-reactive prot...
<p>Patients were grouped according to the number of fulfilled parameters (corticosteroids therapy, n...
<p>Values are mean ± sd unless otherwise indicated. *values are reported as mean ± sd (median).</p><...
*<p>Except where indicated otherwise, values are expressed as the mean (range).</p
Objective To identify and validate clinical baseline predictors associated with inadequate response ...
Baseline characteristics of patients with early RA across DAS28-ESR trajectory groups.</p
Background. In rheumatoid arthritis (RA), prompt diagnosis and initiation of disease-modifying treat...
<p>Values are mean values (SD) or number of patients (%).</p>1<p>Eular Guideline: 1st rheumatologist...
Objective. To compare baseline characteristics, responses and drug survival in patients with early R...
AIMS To develop a population model describing the disease activity (DAS28) time course in patients w...
Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of m...
Objectives: Trial data have provided an evidence base to guide early treatment in RA. Few studies ha...
ObjectivesTrial data have provided an evidence base to guide early treatment in RA. Few studies have...
Abstract Background Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first ch...